Published in Cancer Weekly, August 20th, 2002
"The transcription factor nuclear factor-kappa B (NF-kappaB) confers significant survival potential in a variety of tumors," explained Dr. Nicholas Mitsiades and colleagues working at Harvard Medical School and the associated Dana Farber Cancer Institute. "Several established or novel anti-multiple myeloma (anti-MM) agents, such as dexamethasone, thalidomide, and proteasome inhibitors (PS-341), inhibit NF-kappaB activity as part of their diverse actions."
A specific NF-kappaB inhibitor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.